共 43 条
- [21] Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trialLANCET ONCOLOGY, 2020, 21 (06): : 851 - 860Frumovitz, MichaelObermair, AndreasColeman, Robert L.Pareja, ReneLopez, AldoRibero, ReitanIsla, DavidRendon, GabrielBernardini, Marcus Q.Buda, AlessandroMoretti-Marquez, RenatoZevallos, AlbertVieira, Marcelo A.Zhu, TaoLand, Russell P.Nicklin, JamesAsher, RebeccaRobledo, Kristy P.Gebski, ValRamirez, Pedro T.
- [22] Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2-3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Chen, Qiu-YanMai, Hai-QiangGuo, Shan-ShanLi, Xiao-YunLiu, Li-TingJia, Guo-DongLiu, Sai LanSun, Xue-SongLv, XingXiang, Yan-QunLuo, Dong-HuaSun, RuiQi, YangLiu, QingLi, Ji-BinMo, Hao-YuanGuo, LingZhao, ChongGuo, XiangTang, Lin-Quan
- [23] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (vol 21, pg 1574, 2020)LANCET ONCOLOGY, 2021, 22 (01): : E5 - E5Powles, T.van der Heijden, M. S.Castellano, D.
- [24] Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 TrialEUROPEAN UROLOGY, 2018, 74 (05) : 680 - 681D'Andrea, DavidShariat, Shahrokh F.Soria, Francesco
- [25] Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 TrialEUROPEAN UROLOGY, 2024, 85 (01) : 97 - 98Rosellini, MatteoTassinari, ElisaMarchetti, AndreaMollica, VeronicaMassari, Francesco
- [26] Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cis-platin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Tang, Lin-QuanLiu, Li-TingLiu, HuaiHuang, YingJin, FengXie, Si-YiLi, Yuan-YuanGuo, Shan-ShanLi, Xiao-YunChen, Dong-PingQi, BinYang, Jin-HaoSun, Xue-SongYang, Zhen-ChongLiu, Sai-LanLuo, Dong-HuaLi, Ji-BinChen, Qiu-YanSun, RuiMai, Hai-QiangColevas, A. Dimitrios Dimitrios
- [27] Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trialLANCET ONCOLOGY, 2021, 22 (05): : 716 - 726Lv, XingCao, XunXia, Wei-XiongLiu, Kui-YuanQiang, Meng-YunGuo, LingQian, Chao-NanCao, Ka-JiaMo, Hao-YuanLi, Xian-MingLi, Zi-HuangHan, FeiHe, Yu-XiangLiu, Yu-MengWu, Shao-XiongBai, Yong-RuiKe, Liang-RuQiu, Wen-ZeLiang, HuLiu, Guo-YingMiao, Jing-JingLi, Wang-ZhongLv, Shu-HuiChen, XiZhao, ChongXiang, Yan-QunGuo, Xiang
- [28] Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36 Blood Loss in Robot-assisted Radical Cystectomy: An Important Patient BenefitEUROPEAN UROLOGY, 2019, 75 (02) : E36 - E36Abeysiri, SandaruwaniRichards, Toby
- [29] Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trialLANCET GLOBAL HEALTH, 2020, 8 (09): : E1213 - E1222Patil, VijayNoronha, VanitaDhumal, Sachin BabanraoJoshi, AmitMenon, NandiniBhattacharjee, AtanuKulkarni, SuyashAnkathi, Suman KumarMahajan, AbhishekSable, NileshNawale, KavitaBhelekar, ArtiMukadam, SadafChandrasekharan, ArunDas, SudeepVallathol, DilipD'Souza, HollisKumar, AmitAgrawal, AmitKhaddar, SatvikRathnasamy, NarmadhaShenoy, RamnathKashyap, LakhanRai, Rahul KumarAbraham, GeorgeSaha, SaswataMajumdar, SwaratikaKaruvandan, NaveenSimha, VijaiBabu, VasuElamarthi, PrahaladRajpurohit, AnnuKumar, Kanteti Aditya PavanSrikanth, AnneRavind, RahulBanavali, ShripadPrabhash, Kumar
- [30] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialLANCET ONCOLOGY, 2011, 12 (04): : 333 - 343Machiels, Jean-PascalSubramanian, SomasundaramRuzsa, AgnesRepassy, GaborLifirenko, IgorFlygare, AnnikaSorensen, PerNielsen, TinaLisby, SteenClement, Paul M. J.